For medical-device companies, antitrust risk used to be relatively easy to frame: look at market share, identify overlapping products, assess the deal value, and determine whether an HSR filing is required.
Two Edwards Lifesciences transactions have made the traditional Medical Device M&A playbook look increasingly incomplete.
In 2024, Edwards agreed to acquire JC Medical for $115 million, while separately pursuing the much larger $945 million acquisition of JenaValve. Both companies were developing transcatheter aortic valve replacement devices for aortic regurgitation, or TAVR-AR.
The deals eventually created two very different problems.
The FTC challenged the JenaValve transaction as anticompetitive and won a preliminary injunction in January 2026. Edwards later abandoned the deal. Separately, the FTC alleged that Edwards and Genesis MedTech structured the JC Medical transaction in a way that avoided HSR reporting requirements. In July 2026, the parties agreed to a proposed $12 million penalty, including $10 million from Edwards and $2 million from Genesis. The FTC called it the largest penalty ever for failing to make an HSR filing.
Taken together, the cases send a broader message for Medical Device M&A: regulators are looking not only at what a target sells today, but at what it could become tomorrow, how multiple acquisitions fit together, and whether the structure of a deal accurately reflects its substance.
The First Problem: The Most Important Competitor May Still Be in the Pipeline
The JenaValve case is important because the competitive concern did not depend on the target being a major commercial business.
According to the FTC, Edwards and JenaValve were the only two companies with ongoing U.S. clinical trials for TAVR-AR devices at the time of the proposed acquisition. Edwards had already acquired JC Medical in July 2024, and the proposed $945 million JenaValve acquisition would therefore have brought both leading clinical-stage competitors under Edwards’ control.
That changed the antitrust question.
The issue was no longer simply how much revenue JenaValve generated. The FTC argued that the companies were competing to develop and commercialize a new treatment, including through clinical development and innovation.
On January 9, 2026, after a six-day trial, the federal district court granted the FTC’s request for a preliminary injunction. Edwards subsequently abandoned the transaction. The FTC’s FY2025 HSR report later highlighted the matter as an example of enforcement involving a developing medical-device market.
For companies pursuing Medical Device M&A, the lesson is significant:
A company does not have to be a major seller to be a major competitive asset.
A clinical-stage device may represent future competition because of its clinical data, regulatory pathway, physician relationships, intellectual property, trial network or likelihood of reaching the market.
That means an M&A team looking only at current revenue and market share can miss the most important part of the antitrust analysis.
The Second Problem: $115 Million Was Not Necessarily the Whole Transaction
The JC Medical matter raises a different issue, but one with an equally practical lesson.
Edwards agreed to acquire JC Medical for $115 million in July 2024. That figure was below the then-applicable $119.5 million HSR size-of-transaction threshold.
But Edwards also made a $25 million investment in Genesis, JC Medical’s parent.
The FTC alleged that the investment should have been considered together with the acquisition when determining whether the transaction was reportable. The agency further alleged that Edwards and Genesis did not submit an HSR filing or observe the statutory waiting period before closing the acquisition.
The eventual price of getting that analysis wrong was substantial.
In July 2026, the FTC announced a proposed settlement requiring Edwards, including former Genesis subsidiary JC Medical, to pay $10 million, while Genesis would pay another $2 million. The combined $12 million penalty is the largest ever imposed for failure to make an HSR filing.
And the consequence is not limited to the $12 million.
The proposed judgment also subjects Edwards to additional obligations, including prior-notice requirements for certain future acquisitions involving TAVR-AR clinical-trial companies.
The practical takeaway is simple:
HSR analysis cannot always be based on the headline purchase price.
This is an increasingly important consideration in Medical Device M&A, where acquisitions may involve equity investments, development milestones, licensing arrangements and other interconnected transaction structures.
For transactions involving equity investments, milestone payments or other linked arrangements, deal teams need to examine the economics and structure of the entire transaction.
Why the Two Cases Matter More Together
The most interesting part of the Edwards story is that the FTC did not view these transactions entirely in isolation.
The JC Medical acquisition mattered to the JenaValve case because Edwards already controlled one of the two companies the FTC identified as competing to develop TAVR-AR devices.
At the same time, the JenaValve transaction provides context for why the JC Medical HSR issue mattered. The FTC alleged that Edwards was concerned that HSR review of the JC Medical acquisition could interfere with the timing of its broader acquisition strategy.
That creates an important question for serial acquirers:
What does this deal look like when regulators view it alongside the buyer’s other acquisitions and investments?
A $115 million acquisition may look relatively small when viewed on its own.
But if it gives the buyer control of one of only two companies developing a new technology, and the buyer then seeks to acquire the other for $945 million, the competitive picture changes dramatically.
That is particularly relevant in medical devices, where emerging markets can have very few credible competitors because of high development costs, clinical requirements, regulatory barriers and specialized intellectual property.
For companies pursuing a broader Medical Device M&A strategy, individual transactions therefore cannot always be evaluated in isolation. Regulators may assess how multiple acquisitions and investments collectively reshape competition in an emerging technology market.
The Broader Enforcement Environment Is Getting Harder to Ignore
The Edwards cases are also arriving at a time when merger scrutiny remains significant.
In FY2025, companies reported 2,006 transactions under the HSR Act, according to the FTC and DOJ’s latest annual report. About 31.8% of those transactions were valued at more than $1 billion. The agencies took 18 merger enforcement actions during the year.
Those numbers do not mean every MedTech acquisition is headed for litigation.
In fact, they show the opposite: enforcement is selective.
But selective enforcement makes early analysis more important, not less. A transaction does not need to be enormous to attract attention if the competitive circumstances are unusual.
The agencies’ approach to healthcare and medical-device markets increasingly reflects that reality. The question is not simply whether two companies currently sell competing products. It can also be whether the acquisition removes a meaningful source of future competition or innovation.
For Medical Device M&A teams, this means that transaction value alone is an increasingly incomplete measure of regulatory risk.
What Medical Device M&A Buyers Should Change
The Edwards cases suggest that antitrust diligence needs to expand beyond the traditional checklist.
Start With the Pipeline, Not Just the Product Catalogue
Map companies that are in clinical development, regulatory review or late-stage commercialization. A target with little current revenue may still be one of the most important future competitors in the market.
Look at Acquisitions as a Portfolio
For serial acquirers, every Medical Device M&A transaction should be assessed against the buyer’s existing portfolio.
The question should not only be, “Who does this target compete with?”
It should also be, “Who will we control after this deal, and what happens if we acquire another company in the same space?”
Examine the Economics, Not Just the Labels
The JC Medical matter shows why HSR analysis should examine the complete transaction structure. Purchase price, equity investments, milestones and related arrangements may need to be assessed together.
Treat Internal Documents as Evidence of Competitive Intent
Deal documents, board materials and communications discussing competitors, clinical programs, market positioning, regulatory timing and acquisition strategy can become important in an antitrust investigation.
Bring Antitrust Counsel in Before the Deal Is Designed
This may be the biggest practical lesson.
HSR compliance should not be treated as a formality performed immediately before closing. In concentrated technology markets, the antitrust analysis can influence the structure, timing, valuation and even strategic rationale of the transaction itself.
The New Medical Device M&A Question
The Edwards cases point to a broader shift.
The old question was:
Who sells the most devices today?
The new questions are increasingly:
Who could become a meaningful competitor tomorrow?
Which clinical-stage company could change the market?
Which patents, regulatory assets or clinical programs could enable future entry?
What happens if one buyer acquires several companies in the same emerging technology?
And finally:
Does the legal structure of the transaction accurately reflect its economic substance?
The answers can determine whether a deal closes smoothly, attracts regulatory scrutiny, requires remedies or ends up in court.
For companies involved in Medical Device M&A, that means antitrust diligence can no longer sit separately from IP, regulatory and commercial diligence.
The future of Medical Device M&A will be shaped not just by today’s products, but by tomorrow’s technology. The Edwards cases show that the FTC is prepared to examine future competition, interconnected acquisitions and the economic substance behind complex transactions.
Sources
- FTC: Statement on FTC Victory Halting the Edwards-JenaValve Deal
- FTC/DOJ: FY2025 Hart-Scott-Rodino Annual Report
- FTC: HSR enforcement and Edwards/Genesis $12 million penalty
- FTC: FY2025 HSR Annual Report announcement
- FTC: HSR Premerger Notification Program
- FTC: 2025 HSR thresholds and filing requirements
